Abbott Laboratories have announced the availability of ABT-378/r, a protease inhibitor still in development, on named patient basis in the UK. Physicians may request supply of ABT-378/r to individual patients and there are no restrictions in terms of patient criteria. This named patient program is in addition to the open-label safety evaluation study (M99-046UK) which also provides ABT-378/r to patients meeting the study criteria.

Physicians requiring further information, or needing to request ABT-378/r for individual patients should contact the Named Patient Administrator on 01628 644370.

Source: Abbott Laboratories, 4 April 2000